Related references
Note: Only part of the references are listed.B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
Yemil Atisha-Fregoso et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Effects of Oxytocin on Placebo and Nocebo Effects in a Pain Conditioning Paradigm: A Randomized Controlled Trial
Aleksandrina Skvortsova et al.
JOURNAL OF PAIN (2020)
State-of-the-art treatment of systemic lupus erythematosus
Yoshiya Tanaka
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Lupus nephritis
Hans-Joachim Anders et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions
Fernanda S. Tonin et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2019)
Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks
Sanbao Chai et al.
BMJ OPEN DIABETES RESEARCH & CARE (2019)
Moving Forward With Biologics in Lupus Nephritis
Liliane Hobeika et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2019)
Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus
Shereen Oon et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
Anne Bordron et al.
Oncotarget (2018)
Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients
Weiqing Huang et al.
JCI INSIGHT (2018)
Update on Lupus Nephritis
Salem Almaani et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis
Haitao Zhang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise
Daniel J. Birmingham et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Network meta-analysis: application and practice using Stata
Sungryul Shim et al.
EPIDEMIOLOGY AND HEALTH (2017)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
Brad H. Rovin et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
Pathogenesis of Renal Disease in Systemic Lupus Erythematosus-The Role of Autoantibodies and Lymphocytes Subset Abnormalities
Desmond Y. H. Yap et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
Marianne Frieri et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2015)
Lupus Nephritis in Asia: Clinical Features and Management
Desmond Y. H. Yap et al.
KIDNEY DISEASES (2015)
PROTEINURIA Abate or applaud abatacept in proteinuric kidney disease?
Jochen Reiser et al.
NATURE REVIEWS NEPHROLOGY (2014)
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Xin Yao et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Treatment of Lupus Nephritis With Abatacept
Anca D. Askanase et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
Michael Yellin et al.
ARTHRITIS AND RHEUMATISM (2012)
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
J. P. T. Higgins et al.
RESEARCH SYNTHESIS METHODS (2012)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
BAFF and selection of autoreactive B cells
Zheng Liu et al.
TRENDS IN IMMUNOLOGY (2011)
Checking consistency in mixed treatment comparison meta-analysis
S. Dias et al.
STATISTICS IN MEDICINE (2010)
Pathogenesis of kidney disease in systemic lupus erythematosus
Harini Bagavant et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6
G Jego et al.
IMMUNITY (2003)
Share Paper
